Progressive Fibrosing Interstitial Lung Disease: Clinical Trials

4 trials for Progressive Fibrosing Interstitial Lung Disease, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 1 completed, 1 withdrawn. 1 Not applicable, 1 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Not applicable1Completed 1
Phase 21Active not recruiting 1
Phase 31Withdrawn 1

Follow Progressive Fibrosing Interstitial Lung Disease: new trials by email Literature Review of Progressive Fibrosing Interstitial Lung Disease trials Research Report on Progressive Fibrosing Interstitial Lung Disease

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
ENV-101, Placebo - Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease
Phase 2Active not recruitingEndeavor Biomedicines, Inc.2132024-11-152026-02-24
Hyperpolarized 129-Xenon MRI in Fibrosing Interstitial Lung Disease
Hyperpolarized xenon-129 MRI - Progressive Fibrosing Interstitial Lung Disease
Active not recruitingUniversity of Aarhus302023-10-052025-12-09
Efficacy & Safety of Nintedanib in Patients With Progressive Fibrosing Coal Mine Dust-Induced Interstitial Lung Disease
Nintedanib, Placebo - Progressive Fibrosing Interstitial Lung Disease
Phase 3WithdrawnWest Virginia University2021-11-012025-02-24
Integrating Electronic Patient Reported Biometric Measures (ePReBMs) From Wearable Devices in Respiratory Diseases
ADAMM- RSM Device - Progressive Fibrosing Interstitial Lung Disease, Lung Transplant
Not applicableCompletedUniversity of Alberta82021-07-012023-04-19

Narrower conditions

Bronchiectasis (1)  ·  Cystic Fibrosis (1)  ·  Idiopathic Pulmonary Fibrosis (1)  ·  Pulmonary Fibrosis (1)  ·  Tuberculosis, Pulmonary (1)

Broader conditions

Lung Diseases (2)  ·  Respiratory Tract Diseases (2)  ·  Actinomycetales Infections (1)  ·  Bacterial Infections (1)  ·  Bacterial Infections and Mycoses (1)  ·  Bronchial Diseases (1)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)  ·  Digestive System Diseases (1)  ·  Fibrosis (1)  ·  Genetic Diseases, Inborn (1)  ·  Gram-Positive Bacterial Infections (1)  ·  Infant, Newborn, Diseases (1)  ·  Infections (1)  ·  Lung Diseases, Interstitial (1)  ·  Mycobacterium Infections (1)

Interventions

LY2940680 (1)  ·  nintedanib (1)

Sponsors

Endeavor Biomedicines, Inc. (1)  ·  University of Aarhus (1)  ·  University of Alberta (1)  ·  West Virginia University (1)

Countries

Canada (2)  ·  Argentina (1)  ·  Australia (1)  ·  Austria (1)  ·  Belgium (1)  ·  Denmark (1)  ·  France (1)  ·  Germany (1)  ·  Ireland (1)  ·  Italy (1)  ·  Malaysia (1)  ·  Mexico (1)  ·  New Zealand (1)  ·  South Korea (1)  ·  United Kingdom (1)

Top investigators

Elisabeth Bendstrup, Professor (1)  ·  Giovanni Ferrara, MD (1)  ·  Lisa Lancaster, M.D. (1)  ·  Rahul Sangani, MD (1)